Rapid RV/LV vs EchoNext
AI Verdict
Choose Rapid RV/LV if…
Choose Rapid RV/LV if your primary concern is the rapid assessment and risk stratification of patients with suspected pulmonary embolism (PE). This AI tool excels at automatically measuring right and left ventricle ratios from CTPA scans within minutes, which is crucial for quickly identifying right heart strain and guiding timely treatment decisions for PE patients.
View Rapid RV/LV →Choose EchoNext if…
Choose EchoNext if you need a widely accessible, non-invasive screening tool to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension, from standard ECGs. This tool is ideal for early identification of at-risk patients in various clinical settings, potentially prompting further diagnostic imaging like echocardiograms before symptoms become severe.
View EchoNext →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Rapid RV/LV | EchoNext |
|---|---|---|
| Pricing | Contact vendor for pricing information. | Starts at $600/month |
| Deployment | On-premises (dedicated server or virtual machine) or hybrid (on-premises/cloud with secure link to cloud), connecting to hospital LAN/firewall. | Available through the OpenEvidence clinical decision support platform. |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | 1 AI-estimated | Yes AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
TieBoth tools are designed to integrate into existing clinical workflows. Rapid RV/LV provides rapid, automated measurements from CTPA scans, aiming to reduce variability and standardize assessment. EchoNext analyzes standard ECGs and is available through a clinical decision support platform, suggesting ease of access and integration into routine practice. Without direct user experience data or detailed workflow comparisons, it's difficult to definitively pick a winner, leading to a tie in this dimension.
Clinical Value
EchoNextEchoNext demonstrates superior clinical value by detecting a broader range of hidden structural heart diseases from a widely available and inexpensive test (ECG), including heart failure, valve disease, and pulmonary hypertension. Studies show EchoNext outperforms cardiologists in accuracy for detecting structural heart problems. Rapid RV/LV, while valuable for assessing PE severity, addresses a more specific diagnostic need.
Pricing & Value
EchoNextEchoNext offers transparent tiered pricing starting at $600/month, with options for different organizational sizes and an annual discount. This transparency allows potential users to understand the cost upfront. In contrast, Rapid RV/LV requires contacting the vendor for pricing information, which can be a barrier to evaluating its overall value proposition.
Enterprise Readiness
Rapid RV/LVRapid RV/LV offers flexible deployment options, including on-premises or hybrid solutions, connecting directly to hospital infrastructure. This suggests a robust design for integration into complex enterprise IT environments. EchoNext's deployment through the OpenEvidence platform is also a strong point, but the direct integration options of Rapid RV/LV provide more control and adaptability for large hospital systems.
Innovation
EchoNextEchoNext represents a significant innovation by leveraging AI to detect a broad spectrum of hidden structural heart diseases from routine ECGs, a test traditionally not used for this purpose. This expands the diagnostic capability of a common, inexpensive test, potentially enabling earlier detection and intervention. Rapid RV/LV's automated RV/LV ratio calculation is also innovative, but EchoNext's application to ECGs for broad structural heart disease screening is a more substantial paradigm shift.
Support & Docs
TieNeither the provided structured facts nor the web search results offer specific details regarding the level of customer support, training, or documentation available for either Rapid RV/LV or EchoNext. Therefore, it is not possible to distinguish between the two tools in this dimension.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Rapid RV/LV | EchoNext |
|---|---|---|
| Tool Name | Rapid RV/LV | EchoNext |
| Company | RapidAI (formerly iSchemaView) | Pathway Labs |
| Description | FDA-cleared AI tool for rapid assessment of pulmonary embolism severity by automatically measuring right and left ventricle ratios from CTPA scans. | FDA-cleared AI tool from Pathway Labs that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension. |
| Key Features | AI-powered analysis of CTPA images; Automated measurement of right and left ventricle diameters; Calculation of RV/LV ratio; Annotated images showing ventricular measurements; Rapid results (within minutes of scan); Reduces inter-rater variability; Integration with Rapid PE solution; Triage and notification capabilities (as part of the broader Rapid platform) | AI-powered ECG analysis; Detection of hidden structural heart disease; Identifies heart failure risk; Screens for valve disease; Detects pulmonary hypertension indicators; Utilizes standard 12-lead ECGs; FDA-cleared technology; Non-invasive diagnostic support |
| Specialties | Cardiology, Pulmonology, Radiology | Cardiology, Family Medicine, Hospital Medicine, Internal Medicine |
Videos
Demos, reviews, and walkthroughs featuring Rapid RV/LV and EchoNext.